Biospectator Interview
NetTargets introduced the core platforms N-MAP and N-CAP at the Biopharma Tech concert on May 21st.
For more detailed information please refer to this Korean news article.
Biospectator
19 May 2020
Biospectator Interview
NetTargets introduced the core platforms N-MAP and N-CAP at the Biopharma Tech concert on May 21st.
For more detailed information please refer to this Korean news article.
NetTargets will contribute its proprietary AI-based systems biology modeling technology to WOOJUNGBIO’s Open Innovation Project. By enabling quantitative simulation of biological responses and prediction of drug mechanisms, we are helping to shape a next-generation bioevaluation platform in the era of AI transformation.
NetTargets has been selected as one of the top 10 semifinalists among hundreds of drug discovery startups worldwide. The AI Discovery Award is an annual recognition by Nebius AI, a European AI-centric public cloud provider with global reach.
